Immunotherapy in renal cell carcinoma

Immunotherapy
Annkristin HeinePeter Brossart

Abstract

Treatment of metastatic renal cell cancer is still challenging due to its resistance to conventional therapies, such as radiotherapy or chemotherapy. Immunotherapeutic approaches with IL-2 and/or IFN-alpha have become standard regimens in treating metastatic renal cell cancer. Furthermore, molecularly targeted therapies, such as VEGF-pathway inhibition or use of mammalian target of rapamycin inhibitors, have demonstrated promising results and might become even more important in the following years. Finally, vaccination therapies have gained increasing interest and have been tested in multiple clinical trials. There is a vast choice of different application and production types of these vaccines, ranging from dendritic cell-based principals to the application of naked RNA. The development of new immune-enhancing strategies led to the option of interesting, potent combination regimes. This review has a focus on vaccination therapies in renal cell cancer, especially dendritic cell-based principals, and aims to give an overview of this rapidly changing field of investigation.

References

Jul 1, 1988·Cancer·V MarcoM Gay
Mar 1, 1995·The Journal of Clinical Investigation·G S GilkesonD S Pisetsky
Sep 19, 1996·The New England Journal of Medicine·R J MotzerD M Nanus
Sep 27, 1996·International Journal of Cancer. Journal International Du Cancer·M ThurnherG Bartsch
Jan 1, 1997·Springer Seminars in Immunopathology·D M KlinmanJ Conover
Apr 1, 1998·Nature·J Banchereau, R M Steinman
Nov 26, 1999·British Journal of Cancer·H UemuraE Oosterwijk
Feb 24, 2001·Genes and Immunity·O P KristiansenF Pociot
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E OlsenJ Nichols
Mar 21, 2002·The Lancet Oncology·Paul D Nathan, Tim G Eisen
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I RiniNicholas J Vogelzang
Apr 24, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Edward Y WooCarl H June
Jun 18, 2002·Seminars in Oncology·John A Glaspy
Aug 3, 2002·Nature Reviews. Immunology·Stephen C Jameson
Oct 31, 2002·Nature Immunology·Gavin P DunnRobert D Schreiber
Feb 26, 2003·Gene Therapy·F GrünebachP Brossart
Apr 25, 2003·Cancer·Stephen C Rubin
Jun 5, 2003·International Journal for Parasitology·John DonnellyJeffrey B Ulmer
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Feb 26, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J AtzpodienUNKNOWN Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael B AtkinsMatthew L Sherman
Jul 28, 2004·Stem Cells·Alessio Nencioni, Peter Brossart
Sep 2, 2004·Nature Medicine·Steven A RosenbergNicholas P Restifo
Sep 21, 2004·Cellular and Molecular Life Sciences : CMLS·J-P CarralotS Pascolo
Oct 27, 2004·Blood Reviews·Volker L ReichardtLothar Kanz
Dec 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scott S TykodiBrenda M Sandmaier
Feb 3, 2005·International Journal of Cancer. Journal International Du Cancer·Patrick HoffmannPatrick A Baeuerle

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
surgical resection
biopsies

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.